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Clomiphene, Metformin, or Both for Infertility
in the Polycystic Ovary Syndrome
Richard S. Legro, M.D., Huiman X. Barnhart, Ph.D., William D. Schlaff, M.D., Bruce R. Carr, M.D.,
Michael P. Diamond, M.D., Sandra A. Carson, M.D., Michael P. Steinkampf, M.D., Christos Coutifaris, M.D., Ph.D.,
Peter G. McGovern, M.D., Nicholas A. Cataldo, M.D., Gabriella G. Gosman, M.D., John E. Nestler, M.D.,
Linda C. Giudice, M.D., Ph.D., Phyllis C. Leppert, M.D., Ph.D., and Evan R. Myers, M.D., M.P.H.,
for the Cooperative Multicenter Reproductive Medicine Network*

A bs t r ac t
Background

The polycystic ovary syndrome is a common cause of infertility. Clomiphene and
insulin sensitizers are used alone and in combination to induce ovulation, but it is
unknown whether one approach is superior.
Methods

We randomly assigned 626 infertile women with the polycystic ovary syndrome to
receive clomiphene citrate plus placebo, extended-release metformin plus placebo,
or a combination of metformin and clomiphene for up to 6 months. Medication was
discontinued when pregnancy was confirmed, and subjects were followed until
delivery.
Results

The live-birth rate was 22.5% (47 of 209 subjects) in the clomiphene group, 7.2%
(15 of 208) in the metformin group, and 26.8% (56 of 209) in the combinationtherapy group (P<0.001 for metformin vs. both clomiphene and combination therapy;
P = 0.31 for clomiphene vs. combination therapy). Among pregnancies, the rate of
multiple pregnancy was 6.0% in the clomiphene group, 0% in the metformin group,
and 3.1% in the combination-therapy group. The rates of first-trimester pregnancy
loss did not differ significantly among the groups. However, the conception rate
among subjects who ovulated was significantly lower in the metformin group
(21.7%) than in either the clomiphene group (39.5%, P = 0.002) or the combinationtherapy group (46.0%, P<0.001). With the exception of pregnancy complications,
adverse-event rates were similar in all groups, though gastrointestinal side effects
were more frequent, and vasomotor and ovulatory symptoms less frequent, in the
metformin group than in the clomiphene group.
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Conclusions

Clomiphene is superior to metformin in achieving live birth in infertile women
with the polycystic ovary syndrome, although multiple birth is a complication.
(ClinicalTrials.gov number, NCT00068861.)
n engl j med 356;6
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he polycystic ovary syndrome affects 7 to 8% of women1 and may be the
most common cause of female infertility.2
Anovulation,2 early pregnancy loss,3 and later
pregnancy complications4 have all been implicated in the low fecundity of women with this disorder. Obesity is also common in such women,5
and this condition alone appears to have an adverse effect on reproduction.6,7 The cause of the
polycystic ovary syndrome is poorly understood,
and both the diagnosis and treatment of the disorder are controversial.5,8,9
Women with this syndrome have hyperandro
genism,10 morphologic changes in the ovary (poly
cystic),10 inappropriate gonadotropin secretion (ele
vated levels of circulating luteinizing hormone),11
and insulin resistance with accompanying compensatory hyperinsulinemia.12 Targeting these
metabolic abnormalities has been noted to improve ovulation and fertility in women with this
syndrome.13-17 Results from small head-to-head
trials have suggested that the efficacy of treatment with insulin sensitizers such as metformin
(alone or in combination with clomiphene citrate)
is equal or superior to that of clomiphene alone
for infertility.13,16,17
We designed a trial to test the hypothesis that
treatment of women with the polycystic ovary
syndrome with extended-release metformin is
more likely to result in a live birth than is treatment with clomiphene citrate and that the combination of the two therapies will result in the
highest live-birth rate.

Me thods
Study Design

We have previously described the rationale for
choosing live birth as the primary outcome,18 the
power analysis and main statistical methods,19
the use of infertility screening in the study,20 and
the study design and baseline characteristics of the
subjects.21
The institutional review board at each center
approved the protocol, and all subjects gave written informed consent. All subjects had received
the diagnosis of the polycystic ovary syndrome,
which was defined as oligomenorrhea (with a history of no more than eight spontaneous menses
per year) and hyperandrogenemia (with an elevated testosterone level documented within the previous year in an outpatient setting on the basis
552
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of local laboratory results, with a predetermined
cutoff level set by the principal investigator at each
study site). Subjects were excluded if they had hyperprolactinemia, congenital adrenal hyperplasia,
thyroid disease, or other causes of amenorrhea,
including premature ovarian failure. Clinically
suspected Cushing’s syndrome and androgensecreting neoplasm were additional exclusion
criteria.21
We randomly assigned 626 infertile women
with the polycystic ovary syndrome to one of
three study groups by means of an interactive
voice system. The assignments were stratified according to the study site and the presence or
absence of previous exposure to either of the
study drugs.21 Subjects with other causes of infertility were excluded on the basis of documentation of a normal uterine cavity and at least one
patent fallopian tube; analysis of the semen of
each woman’s current partner was performed
within 1 year before participation in the study,
and a sperm concentration of at least 20 million
per milliliter was required.21 All subjects were in
good health with no major medical disorders.21
Study Drugs

We used extended-release metformin because of
its increased tolerability and proven efficacy in
the treatment of type 2 diabetes.22,23 Extendedrelease metformin (Glucophage XR) plus identical
placebo were provided by Bristol-Myers Squibb.
Overencapsulated clomiphene citrate tablets (purchased from Teva Pharmaceuticals) and matching
placebo capsules were packaged and tested by a
commercial pharmacy supply company (CTS) specifically for the study. Neither manufacturer had
any other role in the study.
Baseline laboratory testing was performed after the subjects had fasted overnight. All specimens were analyzed in a core laboratory.21 In
subjects without recent menses, withdrawal bleeding was induced with a course of oral medroxyprogesterone acetate before the initiation of study
medication. Each subject received a monthly medication package consisting of bottle M (metformin in 500-mg tablets or matching placebo) and
blister pack C (clomiphene in 50-mg tablets or
matching placebo). The two drugs were begun
concurrently. Subjects gradually increased the
dose of the study drug in bottle M until reaching
the maximum dose of four tablets (two tablets
twice a day). Subjects took one tablet a day from
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blister pack C for 5 days, beginning on day 3 of
menses; this dose was maintained if adequate
ovulation was documented. However, in subjects
who had no response or a poor response, the dose
was increased by one tablet a day on a treatmentcycle basis (either after 5 weeks of anovulation
or after a menses until the maximum dose of
three tablets per day was reached).
After the baseline visit, subjects returned each
month for a visit with a limited physical examination, urine pregnancy test, and repeated fasting
blood tests.21 Subjects were instructed to have reg
ular intercourse every 2 to 3 days and to keep a
diary recording intercourse, vaginal bleeding, and
symptoms. The progesterone levels in all subjects
were measured weekly or every other week in local laboratories in order to document ovulation.21
If two consecutive measurements showed elevated
levels of progesterone (above 5 ng per milliliter
[16 nmol per liter]), a weekly pregnancy test was
administered until a positive result or menses
occurred. Induction of withdrawal bleeding with
progestin was scheduled at the discretion of the
principal investigator at each site. Ultrasonography for follicular and endometrial response was
not included in the protocol, and ovulation triggering with human chorionic gonadotropin and
intrauterine insemination were not permitted.
Subjects were treated for up to six cycles, or 30
weeks. All study medication was discontinued if
a pregnancy test was positive. Pregnant subjects
were followed until ultrasonography documented
fetal viability and were then referred for prenatal
care. Investigators reviewed all obstetrical records
to obtain data on birth outcomes. We did not
collect data on the use of other medications during pregnancy.
Outcomes

The primary outcome of the trial was the rate of
live births. Secondary outcomes included the rate
of pregnancy loss, singleton birth, and ovulation
(a serum progesterone level above 5 ng per milliliter during a cycle). A serious adverse event was
defined as any event that was fatal, immediately
life-threatening, or severely or permanently disabling; an event that required or prolonged hospitalization; an overdose (intentional or accidental); a congenital anomaly; pregnancy loss after
12 weeks of gestation; or an event that was
deemed to be serious by the principal investigator
at each site.
n engl j med 356;6

Data Management

All data entry, data management, and analyses
were performed at the Data Coordinating Center
at the Duke Clinical Research Institute. Subjects
were enrolled in the study from November 2002
to December 2004. The last conception was in
June 2005, the last subject finished medication
in August 2005, and the last birth was reported
in February 2006. Data were analyzed according to
the intention-to-treat principle.
Statistical Analysis

We assumed a dropout rate of 15% and the following rates of live birth: 45% in the combinationtherapy group, 30% in the metformin group, and
25% in the clomiphene group. On the basis of
these assumptions, we needed to enroll 678 subjects19 for the study to have a power of 80% with
a type I error rate of 0.05 to detect a 15% absolute
difference in live-birth rates for the following
two primary comparisons: the combination-therapy group versus the next best group and the
metformin group versus the clomiphene group.
Because of limitations in the supply of metformin and matching placebo, the number of subjects was reduced to 626 after the data safety and
monitoring board reviewed blinded data in Novem
ber 2004. Because the live-birth rate was lower
than projected, the final number of subjects provided adequate power (≥80%) to detect the same
15% absolute difference in live-birth rates for the
original two primary comparisons because of the
increased power for detecting the same difference in proportions when the magnitude of the
proportion was decreased.
Either a chi-square test or Fisher’s exact test
was used for testing differences among the three
study groups for categorical variables. A Wilcoxon
rank-sum test was used for testing differences
between two groups, and a Kruskal–Wallis test
was used for testing differences among groups
of three or more. Kaplan–Meier curves were used
for time-to-event analyses. Generalized estimating equations were used for analysis of the ovulation rate to account for correlation of multiple
ovulation cycles for each subject. Post hoc stratification of outcomes was performed on the basis
of the body-mass index (BMI; the weight in kilograms divided by the square of the height in
meters) and presence or absence of previous exposure to medication. All analyses were performed
with SAS software, version 8.2 (SAS Institute).
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Primary Outcome

R e sult s
Study Population

There were no significant differences in baseline
variables among the study groups (Table 1).21
The numbers of subjects who dropped out of the
study were 55 of 209 (26.3%) in the clomiphene
group, 72 of 208 (34.6%) in the metformin group,
and 49 of 209 (23.4%) in the combination-therapy
group (P = 0.07 for the metformin group vs. the
clomiphene group, and P = 0.01 for the metformin
group vs. the combination-therapy group) (Fig. 1).
The reasons for dropout were similar among the
three groups, except that the metformin group
had a higher rate of loss to follow-up than did the
other two groups (P = 0.03 for the comparison with
the clomiphene group, and P = 0.01 for the comparison with the combination-therapy group).

The rate of live birth was significantly lower in
the metformin group than in the clomiphene group
and the combination-therapy group (P<0.001 for
both comparisons), and there was no significant
advantage of the combination therapy over clomiphene (Table 2 and Fig. 2A). However, independently of treatment, subjects with a BMI below
30 had a significantly higher rate of live births
than did women whose BMI was 30 or more
(P<0.001 by univariate analysis) (Fig. 2B). The relationship between treatment and live birth was
similar in post hoc analyses of subgroups stratified according to BMI (<30, 30 to 34, and ≥35)
(see Table 1 of the Supplementary Appendix, available with the full text of this article at www.nejm.
org) and according to previous treatment (Table 2
of the Supplementary Appendix).

Table 1. Baseline Characteristics of the Subjects.*
Clomiphene Group Metformin Group
(N = 209)
(N = 208)

Variable

CombinationTherapy Group
(N = 209)

Biometric features
Age — yr

27.9±4.0

28.1±4.0

28.3±4.0

BMI

36.0±8.9

35.6±8.5

34.2±8.4

Clinically significant hirsutism (FG >16) — no. (%)

81 (38.8)

Waist circumference — cm

76 (36.5)

86 (41.1)

105.0±22.3

102.4±17.6

100.2±18.2

147/208 (70.7)

140/207 (67.6)

148/208 (71.2)

Race or ethnic group — no. (%)†
White
Hispanic or Latino

53/209 (25.4)

61/208 (29.3)

50/209 (23.9)

Black

37/208 (17.8)

40/207 (19.3)

32/208 (15.4)

Asian
American Indian or Alaska Native
Native Hawaiian or Pacific Islander

5/208 (2.4)

5/207 (2.4)

7/208 (3.4)

21/208 (10.1)

27/207 (13.0)

24/208 (11.5)

1/208 (0.5)

0

0

Fertility history
Length of time subject had been attempting conception — mo
Previous therapy for infertility — no. (%)

41.4±39.4

39.0±31.9

40.7±36.0

116 (55.5)

111 (53.4)

116 (55.5)

Conception

77 (36.8)

66 (31.7)

67 (32.1)

Live birth

33 (15.8)

33 (15.9)

28 (13.4)

Pregnancy loss

53 (25.4)

40 (19.2)

45 (21.5)

None

89 (42.6)

87 (41.8)

86 (41.1)

Metformin only

14 (6.7)

16 (7.7)

24 (11.5)

Clomiphene only

67 (32.1)

68 (32.7)

53 (25.4)

Combination therapy

39 (18.7)

37 (17.8)

46 (22.0)

Previous pregnancy — no. (%)

Previous exposure to study drug — no. (%)
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Secondary Outcomes

The rate of ovulation was significantly higher in
the combination group than in either of the singleagent groups (Table 2). Over the course of the
study, the mean (±SD) number of ovulations per
subject was 2.22±1.87 in the clomiphene group,
1.43±1.72 in the metformin group, and 2.80±2.04
in the combination-therapy group (P<0.001 for the
comparisons of the clomiphene and combinationtherapy groups with the metformin group). However, as previously noted, the differences in ovulation rates did not translate into an increase in
the live-birth rate among subjects receiving combination therapy. Rates of conception and live
birth per cycle in which ovulation occurred and
per subject who ovulated were significantly higher
in the clomiphene group and the combinationtherapy group than in the metformin group. All
multiple pregnancies occurred in either the clomiphene group or the combination-therapy group,
although rates were low, and the differences among

the three groups were not significant (P = 0.56 for
the metformin group vs. the clomiphene group,
and P = 1.0 for the metformin group vs. the combination-therapy group).
Over the course of the study, there were no
documented ovulations in 52 of 209 women
(24.9%) in the clomiphene group, 93 of 208
(44.7%) in the metformin group, and 35 of 209
(16.7%) in the combination-therapy group (P<0.001
for both comparisons with the metformin group).
There was no significant linear effect of time on
the rate of ovulation in the metformin group and
the clomiphene group, but there was such an effect on ovulation and live birth in the combination-therapy group (P = 0.002 and P = 0.05, respectively).
Other Treatment Effects

We analyzed metabolic and hormonal effects associated with the medications by comparing baseline data with data recorded at the last study visit

Table 1. (Continued.)
Clomiphene Group Metformin Group
(N = 209)
(N = 208)

Variable

CombinationTherapy Group
(N = 209)

Ultrasonographic findings
Morphologic features of polycystic ovary — no. (%)‡
Ovarian volume —

192 (91.9)

189 (90.9)

192 (91.9)

cm3

Left ovary

10.9±6.9

11.2±6.1

11.2±6.2

Right ovary

11.8±6.9

11.8±5.9

12.5±8.1

Proinsulin — pmol/liter

25.4±24.3

25.5±27.5

23.9±25.7

Insulin — µU/ml

22.6±20.7

24.0±28.4

22.4±30.0

Glucose — mg/dl

89.2±16.5

88.8±17.1

88.9±18.6

SHBG — nmol/liter

29.8±18.7

27.5±14.4

31.8±20.3

Testosterone — ng/dl

61.3±32.0

61.6±25.0

63.1±28.4

Free androgen index§

9.4±7.1

9.9±6.2

9.4±6.8

HOMA-IR¶

5.2±5.3

5.6±8.9

5.6±10.2

Fasting serum levels

* Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. To convert the values for glucose to millimoles per liter, multiply by 0.05551. To convert the values for insulin to picomoles per liter, multiply by 6.
To convert the values for testosterone to nanomoles per liter, multiply by 0.03467. BMI denotes body-mass index (the
weight in kilograms divided by the square of the height in meters), FG Ferriman–Gallwey score, and SHBG sex hormone–binding globulin.
† Race or ethnic group was designated by the subjects. Some subjects chose more than one category, including Hispanic
or Latino.
‡ One or both ovaries were affected.
§ The free androgen index was calculated according to the following formula: (total testosterone [nanomoles per liter] ÷
SHBG [nanomoles per liter]) × 100.
¶ A homeostasis model assessment of insulin resistance (HOMA-IR) was calculated according to the following formula:
(insulin × glucose) ÷ 405.
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4296 Patients prescreened

1316 Provided consent

1226 Completed screening

600 Excluded (some patients for multiple
reasons)
Did not meet inclusion criteria
17 Did not have oligomenorrhea
249 Did not have hyperandrogenemia
9 Were not in good health
1 Was not 18 to 39 yr of age
7 Did not want to seek pregnancy
Did not meet couple-inclusion criteria
95 Did not meet sperm-count criteria
6 Were not able to have regular
intercourse
35 Did not have at least one fallopian
tube and a normal uterine cavity
Met exclusion criteria
20 Were pregnant at the time
of screening
58 Withdrew consent
14 Had type 1 or type 2 diabetes
10 Had hyperprolactinemia
10 Had known 21-hydroxylase deficiency

626 Underwent randomization

209 Received clomiphene

208 Received metformin

209 Received combination
therapy

55 Were withdrawn
15 Were lost to follow-up
21 Had protocol violation
4 Had an adverse effect
6 Had other reason
9 Had problem with partner

72 Were withdrawn
29 Were lost to follow-up
22 Had protocol violation
6 Had an adverse effect
11 Had other reason
4 Had problem with partner

49 Were withdrawn
13 Were lost to follow-up
17 Had protocol violation
7 Had an adverse effect
7 Had other reason
5 Had problem with partner

Figure 1. Enrollment and Outcomes.
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The combination-therapy group had changes similar to those in the metformin group, including
a significant decrease in BMI, levels of testosterone, and the free androgen index and a significant increase in sex hormone–binding globulin
levels (P<0.001 for all comparisons), and a significant decrease in waist circumference (P = 0.004).
Over the course of the study, as compared with
the metformin group, both the clomiphene group
and the combination-therapy group had significant increases in sex hormone–binding globulin
levels (P<0.001 for both comparisons) and decreases in the free androgen index (P<0.001 for
the combination-therapy group vs. the metformin
group, and P = 0.01 for the clomiphene group vs.
the metformin group). As compared with the clomiphene group, the combination-therapy group
had a significant decrease in BMI (P<0.001) and
in levels of testosterone (P<0.001), proinsulin
(P = 0.04), insulin (P = 0.01), and insulin resistance
as determined by HOMA (P = 0.006).
Adverse Events and Pregnancy Complications

Serious adverse events, most of which were compli
cations of pregnancy, were more common among
subjects in the clomiphene group and the combination-therapy group than among those in the
metformin group: 7 of 209 (3.3%), 11 of 209
(5.3%; 1 subject had two events), and 2 of 208
(1.0%), respectively (P = 0.12 for metformin vs.
clomiphene, and P = 0.02 for metformin vs. combination therapy) (Table 4). Gastrointestinal symptoms were more frequent in the groups receiving
metformin, whereas hot flashes and symptoms
associated with ovarian enlargement and ovulation were more common in the groups receiving
clomiphene.
The rates of compliance with the recommended frequency of sexual intercourse ranged from
74 to 76% at the first visit and declined to 54 to
56% at the visit at 6 months. The compliance
rates were similar across groups at all cycles except cycle 4, during which the rates were 71% in
the clomiphene group, 66% in the metformin
group, and 76% in the combination-therapy group
(P = 0.04 for the combination-therapy group vs.
the metformin group).

Dis cus sion
Our findings do not support the hypothesis that
extended-release metformin, either alone or in
n engl j med 356;6

combination with clomiphene citrate, improves
the rate of live birth in women with the polycystic
ovary syndrome. Conception, pregnancy, and live
birth were significantly more likely to occur after
treatment with clomiphene alone than after metformin alone. Adverse-event rates were similar
among the study groups, although serious adverse
events, primarily related to pregnancy, tended to
occur in the groups receiving clomiphene (either
alone or in combination therapy); these groups
had correspondingly higher rates of pregnancy
than did the metformin group.
These results are inconsistent with data from
several other studies reporting benefits of metformin, especially in combination with clomiphene, in stimulating ovulation in women with
the polycystic ovary syndrome.16,17,24-26 Previous
data have generally come from small, primarily
single-center trials18,26,27 that did not assess pregnancy rates but rather focused on metabolic and
hormonal measures, rates of ovulation, or both.26
As in the earlier studies, we found that the groups
receiving metformin (both the metformin group
and the combination-therapy group) had improved
insulin sensitivity (including effects on BMI, proinsulin and insulin levels, and insulin resistance
as determined by HOMA), as compared with the
clomiphene group. However, these effects did not
translate into increased live-birth rates. Instead,
increases in sex hormone–binding globulin levels
were associated with improved live-birth rates.
Our results also differed from those of a
previous randomized trial by Palomba et al.,17
which included 100 subjects and used a design
similar to ours. In that study, the live-birth rate
was 52% after 6 months of metformin, as compared with 18% after clomiphene. In contrast to
our results, levels of fecundity improved over time
among subjects receiving metformin, as compared with clomiphene. Unlike our trial, the study
by Palomba et al. excluded subjects whose BMI
was greater than 30. However, our post hoc analy
sis of women with a BMI of less than 30 also
showed an increased live-birth rate with clomiphene, as compared with metformin.
Our findings regarding the effects of the combination of metformin and clomiphene are consistent with those of another large, multicenter,
randomized trial, reported by Moll et al.,28 in
which the rate of ovulation was the primary outcome. Among 228 subjects with the polycystic
ovary syndrome who were randomly assigned to
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Table 2. Rates of Ovulation, Pregnancy, and Pregnancy Loss.*

Variable

Clomiphene Group
(N = 209)

Metformin Group
(N = 208)

CombinationTherapy Group
(N = 209)

Absolute Difference
between Combination
Therapy and Metformin

no./total no. (%)
Ovulation

% (95% CI)

462/942 (49.0)

296/1019 (29.0)

582/964 (60.4)

31.4 (24.7 to 38.0)

Conception

62/209 (29.7)

25/208 (12.0)

80/209 (38.3)

26.3 (18.4 to 34.2)

Pregnancy

50/209 (23.9)

18/208 (8.7)

65/209 (31.1)

22.4 (15.0 to 29.8)

63/65 (96.9)

−3.1 (−7.3 to 1.1)

Singleton

47/50 (94.0)

18/18 (100.0)

Twins

2/50 (4.0)

0

Triplets

1/50 (2.0)

0

0

0 (−12.7 to 12.7)

0

0

0

0 (−12.7 to 12.7)

47/209 (22.5)

15/208 (7.2)

56/209 (26.8)

19.6 (12.6 to 26.6)

Other
Live birth

2/65 (3.1)

−3.1 (−10.1 to 16.3)

Pregnancy loss
Total losses among subjects who conceived

16/62 (25.8)

10/25 (40.0)

24/80 (30.0)

−10.0 (−31.7 to 11.7)

Loss in first trimester

14/62 (22.6)

10/25 (40.0)

20/80 (25.0)

−14.5 (−35.9 to 6.9)

Biochemical factor or no fetal heart motion

10/62 (16.1)

7/25 (28.0)

13/80 (16.2)

−11.7 (−31.1 to 7.7)

Ectopic pregnancy

2/62 (3.2)

Loss after observed heart motion

2/62 (3.2)

Loss in second or third trimester

2/62 (3.2)

Conception

0

2/80 (2.5)

2.5 (−7.8 to 12.8)

5/80 (6.2)

−5.7 (−19.5 to 8.1)

0

4/80 (5.0)

5.0 (−5.7 to 15.7)

62/462 (13.4)

25/296 (8.4)

80/582 (13.7)

5.4 (1.2 to 9.6)

Singleton pregnancy

47/462 (10.2)

18/296 (6.1)

63/582 (10.8)

4.7 (1.0 to 8.4)

Singleton live birth

47/462 (10.2)

15/296 (5.1)

56/582 (9.6)

4.5 (1.0 to 8.0)

Conception

62/157 (39.5)

25/115 (21.7)

80/174 (46.0)

24.3 (13.7 to 34.9)

Singleton pregnancy

47/157 (29.9)

18/115 (15.7)

63/174 (36.2)

20.5 (10.7 to 30.3)

Singleton live birth

47/157 (29.9)

15/115 (13.0)

56/174 (32.2)

19.2 (9.9 to 28.5)

Visit 1

90/209 (43.1)

45/208 (21.6)

109/209 (52.2)

30.6 (21.8 to 39.4)

Visit 2

90/181 (49.7)

72/189 (38.1)

114/185 (61.6)

23.5 (13.6 to 33.4)

Visit 3

86/159 (54.1)

44/169 (26.0)

97/163 (59.5)

33.5 (23.5 to 43.5)

Visit 4

70/141 (49.6)

49/153 (32.0)

92/144 (63.9)

31.9 (21.1 to 42.7)

Visit 5

58/119 (48.7)

38/138 (27.5)

81/125 (64.8)

37.3 (26.1 to 48.5)

Visit 6

55/99 (55.6)

38/120 (31.7)

74/106 (69.8)

38.1 (26.0 to 50.2)

After Visit 6

13/34 (38.2)

10/42 (23.8)

15/32 (46.9)

23.1 (1.5 to 44.7)

3/25 (12.0)

Events among ovulated cycles

Events among subjects who ovulated

Ovulation per monthly visit

Live birth per monthly visit
Visit 1

10/209 (4.8)

3/208 (1.4)

9/209 (4.3)

2.9 (−0.3 to 6.1)

Visit 2

10/199 (5.0)

3/205 (1.5)

5/200 (2.5)

1.0 (−1.7 to 3.7)

Visit 3

9/189 (4.8)

1/202 (0.5)

11/195 (5.6)

5.1 (1.7 to 8.5)

Visit 4

10/180 (5.6)

2/201 (1.0)

8/184 (4.3)

3.3 (0.1 to 6.5)

Visit 5

2/170 (1.2)

4/199 (2.0)

6/176 (3.4)

1.4 (−1.9 to 4.7)

Visit 6

6/168 (3.6)

2/195 (1.0)

15/170 (8.8)

7.8 (3.3 to 12.3)

0

0

2/155 (1.3)

1.3 (−1.5 to 4.1)

After Visit 6

* Ovulation was defined as a serum progesterone level of more than 5 ng per milliliter. Conception was defined as any positive serum level of
human chorionic gonadotropin. Pregnancy was defined as an intrauterine pregnancy with fetal heart motion, as determined by transvaginal
ultrasonography. Live birth was defined as the delivery of a viable infant.
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P Value

Absolute Difference
between Combination
Therapy and Clomiphene

<0.001

11.4 (4.2 to 18.4)

P Value

Absolute Difference
between Clomiphene
and Metformin

0.003

20.0 (9.1 to 30.9)

<0.001

% (95% CI)

P Value

% (95% CI)

<0.001

8.6 (−0.4 to 17.6)

0.06

17.7 (10.1 to 25.3)

<0.001

<0.001

7.2 (−1.3 to 15.7)

0.10

15.2 (8.3 to 22.1)

<0.001

2.9 (−4.9 to 10.7)

0.96

0.45

−6.0 (−12.6 to 0.6)

0.95

1.0

−0.9 (−9.8 to 8.0)

1.0

4.0 (−9.9 to 17.9)

1.0

1.0

−2.0 (−12.7 to 12.7)

1.0

2.0 (−11.5 to 15.5)

1.0

1.0

0 (−6.4 to 6.4)

1.0

0 (−13.0 to 13.0)

1.0

<0.001

4.3 (−4.0 to 12.6)

0.31

15.3 (8.6 to 22.0)

<0.001

0.35

4.2 (−10.6 to 19.0)

0.58

−14.2 (−36.3 to 7.9)

0.19

0.15

2.9 (−11.2 to 17.0)

0.74

−17.4 (−39.2 to 4.4)

0.10

0.18

0.2 (−12.0 to 12.4)

0.98

−11.9 (−31.7 to 7.9)

0.21

0.80

3.2 (−7.7 to 14.1)

0.97

0.57

−0.7 (−8.0 to 6.6)

0.35

3.1 (−3.8 to 10.0)

0.42

−8.8 (−22.3 to 4.7)

0.14

0.57

1.8 (−6.2 to 9.8)

0.61

3.2 (−7.7 to 14.1)

0.97

0.02

0.4 (−3.8 to 4.6)

0.88

5.0 (0.6 to 9.4)

0.03

0.02

0.6 (−3.1 to 4.3)

0.73

4.1 (0.2 to 8.0)

0.05

0.02

−0.6 (−4.3 to 3.1)

0.77

5.1 (1.4 to 8.8)

0.01
0.002

<0.001

6.5 (−4.1 to 17.1)

0.23

17.8 (7.1 to 28.5)

<0.001

6.3 (−3.8 to 16.4)

0.23

14.2 (4.4 to 24.0)

0.006

<0.001

2.3 (−7.7 to 12.3)

0.66

16.9 (7.5 to 26.3)

<0.001

<0.001

9.1 (−0.4 to 18.6)

0.06

21.5 (12.8 to 30.2)

<0.001

<0.001

0.02

11.6 (1.6 to 21.6)

0.02

0.33

28.1 (17.9 to 38.3)

<0.001

14.3 (2.9 to 25.7)

0.02

17.6 (6.5 to 28.7)

0.002

<0.001

16.1 (3.8 to 28.4)

0.01

21.2 (9.5 to 32.9)

<0.001

<0.001

14.2 (1.1 to 27 .3)

0.03

23.9 (11.1 to 36.7)

<0.001

0.48

14.4 (−6.4 to 35.2)

0.17

<0.001
<0.001

0.04

11.9 (1.8 to 22.0)
5.4 (−5.4 to 16.2)

8.7 (−15.1 to 32.5)

0.07

−0.5 (−4.5 to 3.5)

0.81

3.4 (0.1 to 6.7)

0.04

0.50

−2.5 (−6.2 to 1.2)

0.18

3.5 (0 to 7.0)

0.04

0.001

0.8 (−3.6 to 5.2)

0.70

4.3 (1.1 to 7.5)

0.009

0.05

−1.3 (−5.8 to 3.2)

0.60

4.6 (1.0 to 8.2)

0.008

0.53

2.2 (−0.9 to 5.3)

0.28

−0.8 (−3.3 to 1.7)

0.69

<0.001

5.2 (0.1 to 10.3)

0.04

2.6 (−0.5 to 5.7)

0.15

1.0

1.3 (−1.6 to 4.2)

1.0
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Figure 2. Kaplan–Meier Curves for Live Birth, According to Study Group
(Panel A) and Body-Mass Index (BMI) (Panel B).
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0.96

0.004

207

−1.5±6.9 (−2.4 to −0.5)

<0.001

0.24

0.12

400

0.83

350

P value

300

207

250

Days from Randomization to Live Birth

−0.9±7.6 (−1.9 to 0.2)

200

209

150

Table 3. Absolute Changes in Key Measures between Baseline and Last Visit.*

0

−0.1±12.4 (−1.7 to 1.6)

P<0.001
0.0

Mean change (95% CI)

BMI ≥35

0.1

No. of subjects

BMI 30–34

<0.001

0.2

0.05

BMI <30

P value

0.3

Waist circumference — cm

Rate of Live Birth

0.4

207

0.5

209

Combination-Therapy Group

B

−0.5±1.4 (−0.7 to −0.3)

500

−0.6±2.2 (−0.9 to −0.2)

450

209

400

0.2±1.6 (0 to 0.4)

350

Mean change (95% CI)

300

Metformin Group

250

Clomiphene Group

200

Days from Randomization to Live Birth

BMI

150

Measure

0

No. of subjects

P<0.001

0.72

Metformin

P Value for
Combination
Therapy vs.
Metformin

Rate of Live Birth

0.4

0.18

0.5

0.0

m e dic i n e

P Value for
Clomiphene
vs. Metformin

A

of
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n e w e ng l a n d j o u r na l

<0.001

The

february 8, 2007

The New England Journal of Medicine
Downloaded from nejm.org at VIRGINIA COMMONWEALTH UNIV on January 13, 2015. For personal use only. No other uses without permission.
Copyright © 2007 Massachusetts Medical Society. All rights reserved.

n engl j med 356;6

www.nejm.org

february 8, 2007

201

0.01

2.2±12.6 (0.5 to 4.0)

204

0.08

2.9±22.9 (−0.3 to 6.0)

204

0.18

2.7±28.0 (−1.2 to 6.5)

203

0.01

7.0±39.7 (1.5 to 12.4)

0.40

0.7±10.9 (−0.9 to 2.2)

201

0.78

−0.4±19.3 (−3.0 to 2.3)

201

0.68

−0.8±28.1 (−4.7 to 3.0)

202

0.35

2.2±34.0 (−2.4 to 6.9)

202

<0.001

<0.001
204

−1.6±4.5 (−2.3 to −1.0)

201

<0.001

−7.2±26.3 (−10.9 to −3.6)

−3.3±5.3 (−4.0 to −2.6)

203

0.39

−1.8±29.8 (−5.9 to 2.3)

203

<0.001

<0.001

202
3.3±13.4 (1.5 to 5.2)

204
13.2±15.8 (11.0 to 15.4)

204

0.91

−0.1±11.8 (−1.7 to 1.5)

203

0.61

0.7±20.5 (−2.1 to 3.6)

203

0.96

−0.1±33.7 (−4.7 to 4.5)

204

0.89

−0.3±34.7 (−5.1 to 4.4)

204

<0.001

−3.7±5.9 (−4.5 to −2.9)

204

<0.001

−10.1±30.9 (−14.3 to −5.8)

204

<0.001

18.3±25.0 (14.8 to 21.7)

0.23

0.69

0.26

0.15

<0.001

0.23

<0.001

0.006

0.31

0.04

0.01

0.22

<0.001

0.14

0.14

0.17

0.36

0.29

0.01

0.01

<0.001

* If conception occurred, the last visit was the one before pregnancy was documented. Plus–minus values are means ±SD. To convert the values for glucose to millimoles per liter, multiply by 0.05551. To convert the values for insulin to picomoles per liter, multiply by 6. To convert the values for testosterone to nanomoles per liter, multiply by 0.03467. BMI denotes
body-mass index, and SHBG sex hormone–binding globulin.
† The free androgen index was calculated according to the following formula: (total testosterone [nanomoles per liter] ÷ SHBG [nanomoles per liter]) × 100.
‡ A homeostasis model assessment of insulin resistance (HOMA-IR) was calculated according to the formula (insulin × glucose) ÷ 405.

P value

Mean change (95% CI)

No. of subjects

HOMA-IR‡

P value

Mean change (95% CI)

No. of subjects

Glucose — mg/dl

P value

Mean change (95% CI)

No. of subjects

Proinsulin — pmol/liter

P value

Mean change (95% CI)

No. of subjects

Insulin — µU/ml

P value

Mean change (95% CI)

No. of subjects

Free androgen index†

P value

Mean change (95% CI)

No. of subjects

Total testosterone — ng/dl

P value

Mean change (95% CI)

No. of subjects

SHBG — nmol/liter
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Table 4. Adverse Events.*
Clomiphene
Group

Event

Metformin
Group

CombinationTherapy Group

number (percent)
Before conception in subjects who received a study drug
Total no. of subjects

209

208

209

Serious adverse event
Hemorrhagic corpus luteum cyst†

1 (0.5)

0

0

Hypersensitivity reaction‡

0

1 (0.5)

0

Bronchitis or back pain§

1 (0.5)

0

1 (0.5)

Death¶

0

1 (0.5)

0

Other adverse event
Abdominal distention‖
Abdominal pain or discomfort**

45 (21.5)

56 (26.9)

39 (18.7)

110 (52.6)

123 (59.1)

137 (65.6)

Constipation

32 (15.3)

21 (10.1)

22 (10.5)

Diarrhea**††

48 (23.0)

135 (64.9)

126 (60.3)

Dyspepsia††

9 (4.3)

24 (11.5)

14 (6.7)

Flatulence

38 (18.2)

37 (17.8)

39 (18.7)

Nausea**††

82 (39.2)

128 (61.5)

138 (66.0)

8 (3.8)

15 (7.2)

16 (7.7)

Vomiting**††

28 (13.4)

62 (29.8)

72 (34.4)

Decreased appetite**

17 (8.1)

27 (13.0)

33 (15.8)

Back pain

25 (12.0)

22 (10.6)

22 (10.5)

Dizziness

26 (12.4)

35 (16.8)

34 (16.3)

Stomach discomfort

Impaired sense of taste

10 (4.8)

11 (5.3)

10 (4.8)

Headache

92 (44.0)

88 (42.3)

87 (41.6)

Altered mood or mood swings

32 (15.3)

36 (17.3)

27 (12.9)

Hot flashes‖††

58 (27.8)

32 (15.4)

59 (28.2)

Adnexal pain‖

12 (5.7)

10 (4.8)

4 (1.9)

Anovulatory bleeding‖††

6 (2.9)

18 (8.7)

7 (3.3)

Breast tenderness or pain

41 (19.6)

36 (17.3)

47 (22.5)

Dysmenorrhea or cramps‖††

42 (20.1)

26 (12.5)

43 (20.6)

Sore throat

13 (6.2)

14 (6.7)

8 (3.8)

Respiratory tract infection

27 (12.9)

24 (11.5)

16 (7.7)

Fatigue

38 (18.2)

42 (20.2)

45 (21.5)

50

18

65

After conception (with observed fetal heart motion)
in subjects who discontinued study drug
Total no. of subjects
Serious adverse event before birth

562

Pregnancy loss after 12 weeks

2 (4.0)

0

4 (6.2)

Ectopic pregnancy

2 (4.0)

0

2 (3.1)

Cervical incompetence or preterm labor‡‡

1 (2.0)

0

1 (1.5)

Severe preeclampsia

0

0

2 (3.1)

Congenital anomaly§§

0

0

2 (3.1)
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Table 4. (Continued.)
Clomiphene
Group

Event

Metformin
Group

CombinationTherapy Group

number (percent)
Other adverse event before birth
Preterm labor

4 (8.0)

1 (5.6)

5 (7.7)

Mild preeclampsia

6 (12.0)

1 (5.6)

7 (10.8)

HELLP syndrome

1 (2.0)

0

1 (1.5)

Diet controlled (class A1)

6 (12.0)

1 (5.6)

4 (6.2)

Insulin required (class A2)

3 (6.0)

1 (5.6)

1 (1.5)

Intrauterine growth restriction

0

0

0

Preterm premature rupture of membranes¶¶

1 (2.0)

1 (5.6)

3 (4.6)

Placental abruption

2 (4.0)

0

2 (3.1)

Placenta accreta

0

0

0

Placenta previa

1 (2.0)

0

1 (1.5)

Other placental abnormality

1 (2.0)

1 (5.6)

1 (1.5)

Gestational diabetes

Other pregnancy complication

6 (12.0)

2 (11.1)

4 (6.2)

0

0

0

Postpartum depression requiring intervention

1 (2.0)

0

2 (3.1)

Endometritis

0

0

3 (4.6)

Postpartum hemorrhage

2 (4.0)

0

0

Other disorder

3 (6.0)

1 (5.6)

3 (4.6)

Serious adverse event after birth
Other adverse event after birth

* Diagnoses after pregnancy were made by the treating physician. HELLP syndrome denotes hemolysis, elevated liverenzyme levels, and a low platelet count.
† This event resulted in hospitalization and surgery.
‡ One subject in the metformin group had an anaphylactic reaction during a dinner of shellfish and tuna, resulting in a
visit to the emergency department, during which patient was treated with Benadryl and a corticosteroid and discharged
home. She took a dose of metformin that evening and continued in the study.
§ The subjects with bronchitis (in the clomiphene group) and back pain (in the combination-therapy group) were hospitalized.
¶ One patient in the metformin group had a fatal subarachnoid hemorrhage. She had received the drug for one cycle
and was not pregnant, according to the autopsy report.
‖ P<0.05 for the comparison between combination therapy and metformin.
** P<0.05 for the comparison between combination therapy and clomiphene.
†† P<0.05 for the comparison between clomiphene and metformin.
‡‡ One subject in the clomiphene group had cervical incompetence and delivered at 37 weeks, and one subject in the
combination-therapy group had preterm labor.
§§ One subject, who had severe preeclampsia and nephrolithiasis during her pregnancy, delivered an infant with the
Prader–Willi syndrome, and one patient delivered an infant with a congenital diaphragmatic hernia.
¶¶ Preterm premature rupture of membranes is membrane rupture before contractions begin and at less than 37 weeks’
gestation.

the combination-therapy group. Furthermore,
when ovulation is used as the outcome, the combination of metformin and clomiphene was superior to either clomiphene alone or metformin
alone.13 The pregnancy rates in our trial were
lower than those reported by others,16,17,28,29 perhaps reflecting the inclusion of obese women and
the fact that many of the subjects had a longn engl j med 356;6

standing history of infertility. These factors may
also have contributed to a high rate of pregnancy
complications.6,7,30 Our selection criteria were con
sistent with both National Institutes of Health
criteria and the revised Rotterdam diagnostic cri
teria8,9 for the polycystic ovary syndrome, and
more than 90% of our subjects had polycystic
ovaries on baseline ultrasonography.21 Our cohort
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was similar in age and BMI to the cohort in a
large, multicenter trial that showed a benefit of
the insulin sensitizer troglitazone on ovulatory
frequency in the polycystic ovary syndrome.15
Our study demonstrates the limitations of relying on ovulation rates as a surrogate for livebirth rates.18,27 We found that pregnancy was
approximately twice as likely when ovulation was
induced by clomiphene as when it was induced
by metformin. Our study did not address mechanisms for improved fecundity per ovulation with
clomiphene, as compared with metformin. Multi
ple follicular recruitment, which is characteristic
of the induction of ovulation with clomiphene,31
may have resulted in an increased opportunity for
fertilization and successful implantation (as evidenced by multiple pregnancies only in the groups
receiving clomiphene), as compared with the presumed monofollicular ovulation rate with metformin. We did not perform routine ultrasonography to monitor follicular development because the
addition of such a procedure exceeds the normal
standard of care in this setting and because it
might have led to unblinding in the presence of
multiple follicles.31
Early pregnancy loss may be another mechanism for subfecundity in women with the polycystic ovary syndrome. The observed rate of loss
of intrauterine pregnancies in our study was
similar to or lower than that observed after in
vitro fertilization among women of a similar age
range using their own eggs (approximately 13%)
on the basis of 2003 data from the Society for
Assisted Reproductive Technology.32 Our study
was not adequately powered to detect a difference in the first-trimester loss rate between the
clomiphene group (22.6%) and the metformin
group (40.0%), but our results appear to be inconsistent with those of Palomba et al.,17,29 in
which study medication was likewise discontinued
after a positive pregnancy test. These investigators reported significantly lower first-trimester
loss rates with metformin than with clomiphene
(9.7% vs. 37.5%)17 or fertility treatment with
laparoscopic ovarian diathermy (9.3% vs. 29%),29
although these results were based on small numbers (six events17 and four events,29 respectively).
Another group reported no significant difference
in rates of spontaneous abortion between groups
treated with clomiphene (11%) and combination
therapy (12%).27
Our study cannot address the effects of continu
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ing metformin throughout pregnancy,33 though
our findings raise concern and highlight the need
for randomized trials for this indication.34 Our
results, however, support other studies suggesting an increased rate of pregnancy complications
in women with the polycystic ovary syndrome,4
such as gestational diabetes (12% among subjects
in our study, as compared with 2 to 5% in the
U.S. population35) and preeclampsia (12% in our
study, as compared with 3 to 8% in the U.S.
population36), although obesity clearly contributes
to these risks.7,30
Subjects in our study received extended-release
metformin, and this form of the drug may be less
efficacious in women with the polycystic ovary
syndrome than is immediate-release metformin.37
Our study demonstrates that the tolerability of
extended-release metformin is similar to that of
clomiphene, although metformin had more gastrointestinal side effects and fewer vascular side
effects and ovulation-related symptoms.
In summary, our study supports the use of
clomiphene citrate alone as first-line therapy for
infertility in women with the polycystic ovary
syndrome. We did not find a significant benefit
of combination therapy with clomiphene and
metformin over clomiphene alone with respect
to the live-birth rate. In addition, the results of
our study underscore the limitations of the use
of ovulation as a surrogate marker for live birth
in infertility trials.
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